Cambridge Newswire

Comprehensive Real-Time News Feed for Cambridge, MA.

Results 1 - 20 of 57 for "u:biospace.com" in Cambridge, MA

  1. Akebia Announces $85M Public OfferingRead the original story w/Photo

    Mar 22, 2018 | BioSpace

    Cambridge, Massachusetts-based Akebia Therapeutics announce d plans to offer and sell about $85 million of its common stock in an underwritten public offering. Founded in 2007, Akebia focuses on discovering and developing therapies that leverage the potential of hypoxia inducible factor .

    Comment?

  2. Rheos Medicines Launches with $60 MillionRead the original story w/Photo

    Mar 21, 2018 | BioSpace

    Located in Cambridge, Massachusetts, Rheos Medicines launched with a $60 million Series A financing. The round was backed by Third Rock Ventures .

    Comment?

  3. Voyager Therapeutic's Parkinson's Trial Shows Positive ResultsRead the original story w/Photo

    Mar 8, 2018 | BioSpace

    Voyager Therapeutics , headquartered in Cambridge, Massachusetts, released longer-term data from its ongoing Phase Ib clinical trial of VY-AADC in advanced Parkinson's disease. VY-AADC is Voyager's gene therapy vector.

    Comment?

  4. Magenta Therapeutics and Heidelberg Pharma Team Up for Bone Marrow TransplantsRead the original story w/Photo

    Mar 5, 2018 | BioSpace

    Cambridge, Massachusetts-based Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma GmbH to improve curative bone marrow transplantation. The multi-target research deal will utilize Magenta's stem cell platform and proprietary antibodies with Heidelberg's proprietary ATAC platform to focus on up to four targets.

    Comment?

  5. Generation Bio Raises $100 Million Series B to Finance Non-Viral Gene Therapy ProgramRead the original story w/Photo

    Feb 26, 2018 | BioSpace

    Cambridge, Massachusetts-based Generation Bio closed on a $100 million Series B financing today. It was led by Fidelity Management & Research Company , and joined by Invus, Deerfield Management Company, Casdin Capital, Foresite Capital and Leerink Partners' Affiliates.

    Comment?

  6. AbbVie's Alagolix Hits Primary Endpoints for Uterine FibroidsRead the original story w/Photo

    Feb 20, 2018 | BioSpace

    AbbVie and Neurocrine Biosciences, Inc. ' Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint. Uterine fibroids are abnormal growth in a woman's pelvis, affecting up to 80 percent of women by age 50. The companies have two pivotal Phase III trials ongoing.

    Comment?

  7. AbbVie and Voyager Therapeutics Launch $1.2 Billion+ Alzheimer's PartnershipRead the original story w/Photo

    Feb 19, 2018 | BioSpace

    Chicago-based AbbVie and Cambridge, Massachusetts-based Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer's disease and other neurodegenerative diseases. AbbVie is paying $69 million upfront and up to $155 million in preclinical and Phase I option payments.

    Comment?

  8. 3 Biotechs Facing Stiff Headwinds in 2018Read the original story w/Photo

    Feb 13, 2018 | BioSpace

    The stock market has been rocky recently, but overall the biotech market appears to have been comparatively stable. From about November 10, 2017 to February 12, 2018, the Nasdaq Biotech ETF had risen about three percent.

    Comment?

  9. Sanofi Abandons Multiple Mid-Stage Drug ProgramsRead the original story w/Photo

    Feb 7, 2018 | BioSpace

    Sanofi is ending a mid-stage program for isatuximab for acute lymphoblastic leukemia, and SAR428926, an anti-LAMP1 ADC for solid tumors. With no explanation, the company is ending its next-generation version of Lemtrada, GLD52 for relapsing multiple sclerosis, and SAR100842, an LPA1 receptor antagonist for systemic sclerosis.

    Comment?

  10. Booming Visterra Outgrows Kendall Square Space, Heads to SuburbsRead the original story w/Photo

    Feb 5, 2018 | BioSpace

    Visterra , currently based in Cambridge, Massachusetts' Kendall Square, has outgrown its headquarters and is moving to a site double the size in suburban Waltham, Massachusetts. Visterra is a clinical-stage biopharma company focused on developing anti-infectives using its Hierotope platform.

    Comment?

  11. The 3 Small CRISPR Biotechs That Could Cure 10,000 DiseasesRead the original story w/Photo

    Feb 4, 2018 | BioSpace

    CRISPR is likely to revolutionize medicine. The technology, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a fast and simple way of editing DNA.

    Comment?

  12. 3 High-Risk Biotechs That Could Pop or Drop in 2018Read the original story w/Photo

    Feb 4, 2018 | BioSpace

    Small biotech companies, particularly if they have limited pipelines, are often win-or-lose based on a single clinical trial decision. Todd Campbell, writing for The Motley Fool, looks at three biotech companies that face make-or-break catalysts this year.

    Comment?

  13. Mysterious Biotech Unicorn Moderna Nabs Another $500M, Is Now Worth $7BRead the original story w/Photo

    Feb 1, 2018 | BioSpace

    Feb. 1, 2018 20:00 UTC Moderna Closes $500 Million Equity Financing CAMBRIDGE, Mass.-- -- Moderna Therapeutics , a clinical stage biotechnology company that is pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for high unmet medical needs in patients, today announced that it has raised $500 million in a new funding round. This latest equity financing includes support from new U.S. and international institutional investors, and existing institutional investors.

    Comment?

  14. Voyager Founder and CEO to Step Down, Hunt for New Leader BeginsRead the original story w/Photo

    Jan 31, 2018 | BioSpace

    Dr. Paul is a founder of Voyager, having been with the company for six years since its inception, initially as president of R&D, then as president and CEO since September 2014. In addition to transitioning to an executive science advisor role, in which he will focus on preclinical discovery research and portfolio development, Dr. Paul will continue to serve on Voyager's Board of Directors, and as a member of Voyager's Science & Technology Committee.

    Comment?

  15. Unknown Group of Traders Earned $4.9M Before Sanofi-Bioverativ DealRead the original story w/Photo

    Jan 29, 2018 | BioSpace

    On Jan. 22, Paris, France-based Sanofi acquired Waltham, Massachusetts-based Bioverativ for approximately $11.6 billion. Now the U.S. Securities and Exchange Commission has filed a lawsuit to investigate an unidentified group of stock traders who raked in $4.9 million in "highly suspicious" trades of Bioverative just before the acquisition.

    Comment?

  16. Philips to Move North American HQ and Its 2,000 Employees to CambridgeRead the original story w/Photo

    Jan 11, 2018 | BioSpace

    Netherlands-based health tech company Royal Philips will move its North American headquarters to Cambridge, Mass. from Andover, Mass.

    Comment?

  17. Germany's Novaliq Sets Up U.S. Subsidiary in Cambridge, MassachusettsRead the original story w/Photo

    Jan 8, 2018 | BioSpace

    Novaliq GmbH , a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the formation of its new subsidiary, Novaliq Inc., which will be located in Cambridge, Massachusetts, U.S. As an emerging leader in the field of ophthalmology, Novaliq is currently pursuing two late-stage clinical trials in the United States: Novaliq's ESSENCE phase 2b/3 clinical trial is a pivotal randomized, double-masked, vehicle-controlled, multi-center trial, designed to evaluate the safety, efficacy and tolerability of topical CyclASolA for the treatment of dry eye disease .

    Comment?

  18. What You Need to Know About Relay TherapeuticsRead the original story w/Photo

    Jan 4, 2018 | BioSpace

    Based in Cambridge, Mass. and founded in February 2016, Relay Therapeutics focuses on developing therapeutics involving protein motion.

    Comment?

  19. 3 Biotechs Seeking $271M IPO in the New YearRead the original story w/Photo

    Jan 1, 2018 | BioSpace

    Individuals aren't the only ones making New Year's Resolutions. Three biotech companies want to start out the new year with a new start-as publicly traded companies.

    Comment?

  20. Top 5 Massachusetts Biotechs That Jumped at Least 250% in 2017Read the original story w/Photo

    Dec 10, 2017 | BioSpace

    Biotech companies in general had a good year in 2017. Massachusetts is one of the big centers for biotech companies, with the San Francisco Bay Area being the other.

    Comment?

Cambridge Job Listings
View or post Cambridge job listings on Topix.
Cambridge Real Estate
News, listings, and foreclosures in Cambridge from Topix.
Cambridge Mortgages
Find mortgage rates in Cambridge on Topix.